HOME >> MEDICINE >> NEWS
MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology

St. Louis, MO, May 31, 2001--MetaPhore Pharmaceuticals, Inc. today announced that it has received FDA approval of its Investigational New Drug (IND) application to conduct clinical trials in the U.S. to evaluate M40403, one of its enzyme mimetic compounds.

MetaPhore has initiated a Phase I study to test the safety and tolerability and to determine the pharmacokinetics of the compound in normal, healthy human subjects, as a precursor to Phase II trials in which M40403 will be tested as a co-therapy with interleukin-2 (IL-2) for advanced skin and end-stage kidney cancers. This study is the first human clinical trial for MetaPhore and the companys proprietary family of enzyme mimetic compounds that effectively mimic the action of one of the bodys primary free-radical fighting mechanisms, the natural enzyme superoxide dismutase (SOD).

In addition to cancer, MetaPhore is developing these compounds as drug candidates for pain and other diseases and conditions that have been associated with free-radical damage to tissues and cells.

The opening of this IND marks a major step for MetaPhore and our SOD enzyme mimetic program. For many years, we have understood the free-radical fighting power of the bodys natural SOD enzymes, but only recently have we been able to reproduce that benefit in a stable and selective drug form, said Denis Forster, Chief Operating Officer of MetaPhore. These novel therapeutics have tremendous potential, based on the growing body of research linking free-radical mediated damage with a wide range of acute and chronic disease states.

Preclinical studies in animals, including several recently presented at the American Association for Cancer Research at the end of March, have shown that M40403 significantly improves the effectiveness of IL-2, an approved treatment for inoperable metastatic melanoma and metastatic renal-cell carcinoma. Approximately 80,000 cases of melanoma and renal-cell carcinoma are diagnosed in th
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
30-May-2001


Page: 1 2 3

Related medicine news :

1. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
2. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. Pharmaceuticals and personal care products
6. Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. NIAID initiates trial of experimental avian flu vaccine
11. American Academy of Neurology initiates health literacy training for neurologists

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... 03, 2020 , ... MemoryCare.com, a comprehensive resource for caregivers ... Facilities in Louisville, KY. The guide identifies 17 memory care communities based on ... Alzheimer’s Association , 5.6 million people age 65 and older are living ...
(Date:9/2/2020)... ... September 02, 2020 , ... RAM Technologies, ... administering Medicare Advantage and Special Needs plans, is proud to support the 2020 ... Plans (AHIP). RAM is supporting the event as a sponsor and exhibitor and ...
(Date:9/1/2020)... ... , ... KitoTech Medical, a Seattle-based medical device company, announced ... used to accelerate the commercialization of its microMend® family of wound closure products. ... expand its customer base of healthcare systems as well as independent hospitals and ...
(Date:9/1/2020)... ... September 01, 2020 , ... As fall and winter swiftly ... Cohn Health Institute has taken this time to expand and grow into a ... Anniversary, the Cohn Health Institute will be relaunching its brand new website, expanding its ...
(Date:8/31/2020)... ... August 31, 2020 , ... Cardiothoracic surgeons at Allegheny ... from Carnegie Mellon University (CMU) to develop a new heart monitoring device designed ... heart surgery. , The AGH/CMU team was recently awarded a “Trailblazer” grant from ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... ... ... While coronavirus cases continue to increase across the country, blood drives are ... Because about 80% of blood donations are made at drives hosted by these groups, ... hosts to ensure blood products are readily available for patients. , Those interested ...
(Date:9/1/2020)... ... September 01, 2020 , ... September is National Ovarian Cancer Awareness Month. ... any other cancer of the female reproductive system. The American Cancer Society estimates ... 14,000 women will die from this disease. Throughout the month of September, Women’s ...
(Date:8/31/2020)... ... 31, 2020 , ... If you live in New York City you will always pay more ... it’s the law of supply and demand, but are plastic surgeons in New York worth ... of their patients that make the four-hour trip to have expert aesthetic treatments by some ...
Breaking Medicine Technology:
Cached News: